Trial results for evolocumab (Repatha) in renal transplant recipients with hyperlipidemias were posted on ClinicalTrials.gov on 2026-04-16. The study demonstrated a mean reduction in LDL cholesterol from baseline of -46.6% over 12 months in participants treated with evolocumab.
Background
Cardiovascular disease is a significant concern after renal transplantation, contributing to over 30% of deaths. Elevated lipid levels, or hyperlipidemia, are commonly observed post-transplantation, with immunosuppressive medications playing a key role in their development or worsening. Reducing serum LDL cholesterol is a well-established strategy to decrease cardiovascular morbidity and mortality in the general population.
Trial design
The study, identified as NCT04608474, was a Phase 4 trial titled "Lipid Management in Renal Transplant Recipients Using Evolocumab." It enrolled 81 participants with hyperlipidemias. The intervention studied was evolocumab. The trial's overall status was COMPLETED.
Key results
The trial measured changes in LDL cholesterol from baseline:
- The "Percent Change in LDL Cholesterol From Baseline to 12 Months" for the evolocumab group showed a mean reduction of -46.6% (Standard Deviation: 25.9).
- The "Absolute Change in LDL Cholesterol From Baseline to 12 Months" for the evolocumab group was a mean reduction of -61.8 mg/dL (Standard Deviation: 38.5).
The study also reported the number of participants achieving specific LDL cholesterol targets:
- 46 participants achieved LDL cholesterol < 70 mg/dL at any time during follow-up.
- 20 participants achieved LDL cholesterol < 70 mg/dL at any time during follow-up.
What this means
The results suggest that evolocumab effectively lowers LDL cholesterol levels in renal transplant recipients suffering from hyperlipidemias. The observed mean percentage and absolute reductions in LDL cholesterol indicate a potential benefit for managing dyslipidemia in this high-risk patient population, where cardiovascular disease is a leading cause of mortality.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04608474, titled "Lipid Management in Renal Transplant Recipients Using Evolocumab," were posted on 2026-04-16 on clinicaltrials.gov.